
Humacyte (HUMA) Stock Forecast & Price Target
Humacyte (HUMA) Analyst Ratings
Bulls say
Humacyte is supported by improving commercial traction, with 3Q26 revenue of about $1.0M rising 36.5% year over year, roughly 60 Symvess units sold, and hospital ordering sites increasing 44% quarter over quarter to 49, while management expects revenue to double in 4Q26 as at least 20 new hospital sites come on board. Its fundamental thesis is strengthened by the V012 interim data, where the ATEV achieved 220 catheter-free days versus 129 for standard care, met the primary efficacy endpoint with p=0.00070, and showed a favorable safety profile with lower infection rates and zero access-associated infections in the ATEV cohort. The company also has a meaningful near-term catalyst in the November supplemental BLA filing for dialysis access, which could unlock a much larger market than vascular trauma while operating spend reductions and the $50M equity offering help reduce financial overhang.
Bears say
Humacyte is facing a fundamental mismatch between commercial ambition and execution, as 2Q revenue of $0.4 million fell well below the $1.1 million consensus and the company’s $1.2 million estimate, while it still reported operating losses since inception and may not achieve profitability for several years. The outlook is further pressured by clinical, regulatory, and manufacturing uncertainty, including the risk of longer trial enrollment, poor clinical outcomes, and whether a comparability demonstration between the former and new manufacturing process will be accepted by the FDA. Although restructuring is forecasted to reduce spending by $14.3 million for the remainder of 2026, commercialization remains difficult to predict, and the company may need additional capital and dilution while market adoption for ATEVs remains uncertain.
This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.
Humacyte (HUMA) Analyst Forecast & Price Prediction
Start investing in Humacyte (HUMA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Humacyte (HUMA) Forecast
Humacyte (HUMA) Analyst Forecast & Price Prediction
Start investing in Humacyte (HUMA)
Order type
Buy in
Order amount
Est. shares
0 shares